Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ drug effects
Antibody Formation
/ drug effects
Antibody Specificity
/ drug effects
COVID-19
/ complications
Case-Control Studies
Female
Follow-Up Studies
Hematologic Neoplasms
/ complications
Hospitalization
Humans
Immunity, Humoral
/ drug effects
Italy
/ epidemiology
Longitudinal Studies
Male
Middle Aged
Rituximab
/ pharmacology
SARS-CoV-2
/ immunology
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
14 09 2021
14 09 2021
Historique:
received:
11
06
2021
accepted:
27
08
2021
revised:
14
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
24
9
2021
Statut:
epublish
Résumé
The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.
Identifiants
pubmed: 34521813
doi: 10.1038/s41408-021-00546-9
pii: 10.1038/s41408-021-00546-9
pmc: PMC8438656
doi:
Substances chimiques
Antibodies, Viral
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
151Subventions
Organisme : Regione Lombardia (Region of Lombardy)
ID : Risposta immune in pazienti con COVID-19 e co-morbidità
Informations de copyright
© 2021. The Author(s).
Références
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
J Cancer. 2021 Mar 1;12(8):2450-2455
pubmed: 33758621
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Clin Microbiol Infect. 2004 Dec;10(12):1062-6
pubmed: 15606632
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
Lancet. 2021 Mar 20;397(10279):1075-1084
pubmed: 33743869
Cancer. 2020 Dec 1;126(23):5069-5076
pubmed: 32910456
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Cancer Sci. 2020 Sep;111(9):3379-3385
pubmed: 32619034
Chin Med J (Engl). 2020 Jul 5;133(13):1575-1594
pubmed: 32366746
Leukemia. 2020 Nov;34(11):3047-3049
pubmed: 32855439
Br J Haematol. 2020 Oct;191(2):194-206
pubmed: 32678948
Leukemia. 2021 Jan;35(1):289-292
pubmed: 33299142
J Med Virol. 2020 Oct;92(10):2227-2231
pubmed: 32484958
BMJ Case Rep. 2021 Mar 4;14(3):
pubmed: 33664039
Microorganisms. 2021 Mar 08;9(3):
pubmed: 33800489
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
EClinicalMedicine. 2021 Feb;32:100734
pubmed: 33589882
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
J Med Virol. 2021 Jul;93(7):4585-4591
pubmed: 33595119
Haematologica. 2020 Dec 17;106(5):1457-1460
pubmed: 33327714
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
J Hematol Oncol. 2020 Oct 8;13(1):133
pubmed: 33032660
Lancet Haematol. 2021 Jun;8(6):e389-e392
pubmed: 33887255
Sci Adv. 2021 Jul 30;7(31):
pubmed: 34330709
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
Clin Transl Immunology. 2021 Jul 05;10(7):e1306
pubmed: 34257967